231 related articles for article (PubMed ID: 37017700)
1. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
[TBL] [Abstract][Full Text] [Related]
2. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
3. The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
Pan J; Song M; Yang L; Zhao Y; Zhu Y; Wang M; Chen F
Eur Radiol; 2023 Aug; 33(8):5801-5811. PubMed ID: 36894754
[TBL] [Abstract][Full Text] [Related]
4. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
5. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
[TBL] [Abstract][Full Text] [Related]
6. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
[TBL] [Abstract][Full Text] [Related]
7. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
[TBL] [Abstract][Full Text] [Related]
8. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
[TBL] [Abstract][Full Text] [Related]
9. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
[TBL] [Abstract][Full Text] [Related]
10. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
11. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
15. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
16. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
[TBL] [Abstract][Full Text] [Related]
17. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.
Choi SH; Byun JH; Kim SY; Lee SJ; Won HJ; Shin YM; Kim PN
Invest Radiol; 2016 Aug; 51(8):483-90. PubMed ID: 26885632
[TBL] [Abstract][Full Text] [Related]
18. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
19. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
20. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
